A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model
作者:Shigeki Kunikawa、Akira Tanaka、Yuji Takasuna、Mamoru Tasaki、Noboru Chida
DOI:10.1016/j.bmc.2018.09.029
日期:2018.11
Protein kinase C theta (PKCθ) plays a critical role in T cell signaling and is an attractive target for the treatment of T cell-mediated diseases such as transplant rejection and autoimmune disease. To identify PKCθ inhibitors, we focused on the 2,6-diamino-3-carbamoyl-5-cyanopyrazine derivative 2, which exhibited moderate PKCθ inhibitory activity. Optimization of 2 identified the 2,4-diamino-5-cyanopyrimidine
蛋白激酶C theta(PKCθ)在T细胞信号传导中起关键作用,并且是治疗T细胞介导的疾病(如移植排斥和自身免疫性疾病)的有吸引力的靶标。为了鉴定PKCθ抑制剂,我们集中于2,6-二氨基-3-氨基甲酰基-5-氰基吡嗪衍生物2,其表现出中等的PKCθ抑制活性。2的优化确定了2,4-二氨基-5-氰基嘧啶衍生物16c,该衍生物表现出有效的PKCθ抑制活性,并且对其他PKC同工酶表现出良好的选择性。在体内大鼠异位心脏移植模型中,化合物16c延长了移植物的存活。